Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04764669 · ClinicalTrials.gov registry record · Phase 2
A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT04764669 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 34 participants.
The verdict
NCT04764669, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of study is to demonstrate the pharmacodynamic (PD) effects of E2027 on cerebrospinal fluid (CSF) cyclic guanosine monophosphate (cGMP) in participants with DLB and PDD with and without amyloid copathology after 9 weeks of treatment.
Interventions
- DRUG E2027
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2021-02-25 |
| Est. Completion | 2022-01-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04764669
The ClinicalTrials.gov registry entry for NCT04764669 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which E2027 is the first listed.
NCT04764669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04764669 about?
NCT04764669 is a clinical study titled "A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology". The purpose of study is to demonstrate the pharmacodynamic (PD) effects of E2027 on cerebrospinal fluid (CSF) cyclic guanosine monophosphate (cGMP) in participants with DLB and PDD with and without amyloid copathology after 9 weeks of treatment.
What is the current status of trial NCT04764669?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2021-02-25. Estimated completion is 2022-01-27.
What interventions are being tested in trial NCT04764669?
The interventions under investigation include: E2027 (DRUG).
Who is sponsoring clinical trial NCT04764669?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.